Next generation targeted protein therapeutics







                                                                            News


Press Releases

News

Publications  

Download Fact Sheet

Download Company Presentation

Media Inquiries
Please contact:
Leah Grant





Press Releases
11/07/2013
ImmunGene Raises $9 Million in Series A Financing
 
06/03/2013
ImmunGene and Collaborators Report Positive Results in Pre-clinical Studies of Novel Anti-CD20 Antibody-Interferon Alpha Fusion Protein
 
06/03/2013
ImmunGene and Collaborators Report Positive Results in Pre-clinical Studies of Novel Anti-CD20 Antibody-Interferon Alpha Fusion Protein
 
05/22/2013
The Leukemia & Lymphoma Society, Valor Biotherapeutics and ImmunGene Create Partnership to Advance Novel Therapy for Non-Hodgkin Lymphoma Patients
 
11/13/2012
Caliber and ImmunGene Launch Valor Biotherapeutics, a Joint Venture to Develop Antibody-Interferon Fusion Therapeutics to Treat Cancers

02/11/2011
ImmunGene's Interferon Payload Technology Platform Featured in BioCentury Magazine

01/05/2011
ImmunGene Announces Multi-Target R&D Collaboration With Cephalon Australia for Interferon Payload Technology

Latest News

11/23/2010
ImmunGene Receives $244,479 Grant Under The Patient Protection And Affordable Care Program For Its Anti-Cancer Technology

11/11/2010
ImmunGene's Pipeline of Next Generation Cancer Therapeutics Featured in BioWorld Today



Publications

Targeting IFN-alpha to B Cell Lymphoma cells by a Tumor-Specific Antibody Elicits Potent Antitumor Activities
By Tzu-Hsuan Huang, Koteswara R. Chintalacharuvu, and Sherie L. Morrison
The Journal of Immunology, 2007, 179: 6881– 6888 Download PDF

Targeted delivery of interferon-alpha via fusion to anti-CD20 results in potent antitumor activity against B-cell lymphoma.
By Xuan C, Steward KK, Timmerman JM, Morrison SL.
Blood. 2010 Apr 8;115(14):2864-71 Download PDF